CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)

Pravin Chaturvedi, PhD, Napo’s and Jaguar’s Chief Scientific Officer and Chair of the Scientific Advisory Board

“The scientific rationale for investigating Napo's liquid oral formulation of crofelemer to reduce intestinal fluid losses”

Dr. Christos Tzivinikos, MD DCH FRCPCH MSc CEBP, Consultant Pediatric Gastroenterologist, Founder of the Pediatric GI Department at Al Jalila Children’s Specialty Hospital, and Clinical Associate Professor at Mohammed Bin Rashid University of Medicine and Health Sciences

“The significant disease heterogeneity and the importance of the ongoing randomized double-blind placebo-controlled crossover study in MVID patients required to support the regulatory requirements for the company”